Ardelyx, Inc. (ARDX)
NASDAQ
Market Cap
$1.24B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
142 of 966
Rank in Industry
98 of 554
Largest Insider Buys in Sector
ARDX Stock Price History Chart
ARDX Stock Performance
About Ardelyx, Inc.
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Insider Activity of Ardelyx, Inc.
Over the last 12 months, insiders at Ardelyx, Inc. have bought $996,598 and sold $13.57M worth of Ardelyx, Inc. stock.
On average, over the past 5 years, insiders at Ardelyx, Inc. have bought $1M and sold $5.35M worth of stock each year.
Highest buying activity among insiders over the last 12 months: MOTT DAVID M (director) — $10.96M.
The last purchase of 215,868 shares for transaction amount of $996,598 was made by MOTT DAVID M (director) on 2024‑11‑13.
List of Insider Buy and Sell Transactions, Ardelyx, Inc.
| 2024-11-25 | Sale | President & CEO | 25,000 0.0107% | $5.38 | $134,483 | +5.90% | ||
| 2024-11-20 | Sale | President & CEO | 31,980 0.0132% | $4.79 | $153,328 | +11.79% | ||
| 2024-11-20 | Sale | See Remarks | 4,941 0.002% | $4.79 | $23,690 | +11.79% | ||
| 2024-11-20 | Sale | Chief Medical Officer | 7,366 0.003% | $4.79 | $35,316 | +11.79% | ||
| 2024-11-20 | Sale | Chief Financial Officer | 5,260 0.0022% | $4.79 | $25,219 | +11.79% | ||
| 2024-11-20 | Sale | See Remarks | 7,046 0.0029% | $4.79 | $33,782 | +11.79% | ||
| 2024-11-20 | Sale | Chief Development Officer | 7,184 0.003% | $4.79 | $34,444 | +11.79% | ||
| 2024-11-13 | director | 215,868 0.0924% | $4.62 | $996,598 | +22.22% | |||
| 2024-11-11 | Sale | President & CEO | 2,743 0.0012% | $4.90 | $13,441 | +9.41% | ||
| 2024-11-06 | Sale | Chief Development Officer | 27,171 0.0109% | $6.10 | $165,743 | -17.87% | ||
| 2024-11-04 | Sale | Chief Development Officer | 27,172 0.0115% | $5.95 | $161,673 | -9.17% | ||
| 2024-10-28 | Sale | President & CEO | 25,000 0.0109% | $5.91 | $147,740 | -1.00% | ||
| 2024-10-11 | Sale | President & CEO | 7,500 0.003% | $6.01 | $45,075 | -5.96% | ||
| 2024-09-27 | Sale | Chief Development Officer | 49,564 0.0229% | $6.92 | $342,983 | -11.88% | ||
| 2024-09-26 | Sale | President & CEO | 3,000 0.0013% | $6.07 | $18,210 | +4.78% | ||
| 2024-09-13 | Sale | Chief Development Officer | 5,312 0.0022% | $6.26 | $33,254 | -6.66% | ||
| 2024-09-11 | Sale | President & CEO | 35,000 0.0147% | $5.61 | $196,399 | 0.00% | ||
| 2024-08-27 | Sale | President & CEO | 7,500 0.0032% | $6.22 | $46,635 | -5.39% | ||
| 2024-08-20 | Sale | President & CEO | 32,225 0.0131% | $5.86 | $188,848 | -3.59% | ||
| 2024-08-20 | Sale | See Remarks | 4,969 0.002% | $5.86 | $29,120 | -3.59% |
Insider Historical Profitability
37.65%
| MOTT DAVID M | director | 1425465 0.6018% | $5.24 | 9 | 0 | +20.54% |
| RAAB MICHAEL | President & CEO | 1150385 0.4857% | $5.24 | 1 | 51 | +247.57% |
| Rodriguez Susan | Chief Commercial Officer | 449092 0.1896% | $5.24 | 0 | 16 | |
| Blanks Robert | See Remarks | 314421 0.1327% | $5.24 | 0 | 25 | |
| Williams Laura A | Chief Medical Officer | 308745 0.1304% | $5.24 | 1 | 14 | +247.57% |
| Renz Justin A | Chief Financial Officer | 291139 0.1229% | $5.24 | 1 | 19 | +247.57% |
| GRAMMER ELIZABETH A | See Remarks | 185334 0.0782% | $5.24 | 2 | 40 | +116.79% |
| Rosenbaum David P. | Chief Development Officer | 151373 0.0639% | $5.24 | 1 | 55 | +247.57% |
| Felsch Robert Ora | See Remarks | 91560 0.0387% | $5.24 | 1 | 8 | +247.57% |
| BARRIS PETER J | 10 percent owner | 8752543 3.6953% | $5.24 | 3 | 1 | +14.35% |
| BARRETT M JAMES | 10 percent owner | 8752543 3.6953% | $5.24 | 3 | 1 | +14.35% |
| KERINS PATRICK J | 10 percent owner | 8752543 3.6953% | $5.24 | 3 | 0 | +14.35% |
| KOLLURI KRISHNA KITTU | 10 percent owner | 8752543 3.6953% | $5.24 | 3 | 1 | +14.35% |
| New Enterprise Associates 12, Limited Partnership | 10 percent owner | 8752543 3.6953% | $5.24 | 4 | 0 | +10.76% |
| DRANT RYAN D | 10 percent owner | 7488893 3.1618% | $5.24 | 1 | 0 | +13.2% |
| MAKOWER JOSHUA | 10 percent owner | 2665520 1.1254% | $5.24 | 2 | 0 | +14.92% |
| Weller Harry R | 10 percent owner | 2665520 1.1254% | $5.24 | 2 | 0 | +14.92% |
| Viswanathan Ravi | 10 percent owner | 2665520 1.1254% | $5.24 | 2 | 0 | +14.92% |
| Sonsini Peter W. | 10 percent owner | 2665520 1.1254% | $5.24 | 2 | 0 | +14.92% |
| Florence Anthony A. Jr. | 10 percent owner | 2665520 1.1254% | $5.24 | 2 | 0 | +14.92% |
| Sakoda Jon | 10 percent owner | 2665520 1.1254% | $5.24 | 2 | 0 | +14.92% |
| NEA 15 GP, LLC | 10 percent owner | 2665520 1.1254% | $5.24 | 2 | 0 | +14.92% |
| SANDELL SCOTT D | 10 percent owner | 2258850 0.9537% | $5.24 | 3 | 8 | +14.35% |
| BASKETT FOREST | 10 percent owner | 2258850 0.9537% | $5.24 | 3 | 8 | +14.35% |
| SCHULTZ PETER G | director | 907429 0.3831% | $5.24 | 1 | 0 | +13.2% |
| Seeto Reginald | Chief Operating Officer | 149885 0.0633% | $5.24 | 0 | 1 | |
| Kaufmann Mark | Chief Financial Officer | 141418 0.0597% | $5.24 | 0 | 8 | |
| Jacobs Jeffrey W | Chief Scientific Officer | 119483 0.0504% | $5.24 | 0 | 21 | |
| CMEA Ventures VII LP | 10 percent owner | 80990 0.0342% | $5.24 | 1 | 2 | 0% |
| Korner Paul | EVP, Chief Medical Officer | 54623 0.0231% | $5.24 | 0 | 1 | |
| RINGOLD GORDON | director | 25000 0.0106% | $5.24 | 3 | 0 | +13.85% |
| JUE GEORGE | VP, Operations | 24134 0.0102% | $5.24 | 0 | 1 | |
| Caldwell Jeremy S | EVP, Chief Scientific Officer | 17985 0.0076% | $5.24 | 0 | 3 | |
| Bertrand William C JR | director | 5000 0.0021% | $5.24 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Janus Henderson | $160.86M | 9.42 | 22.05M | -10.59% | -$19.05M | 0.08 | |
| BlackRock | $124.8M | 7.31 | 17.1M | +1.91% | +$2.34M | <0.01 | |
| State Street | $102.85M | 6.02 | 14.09M | -17.62% | -$22M | <0.01 | |
| The Vanguard Group | $97.76M | 5.72 | 13.39M | +2.81% | +$2.67M | <0.01 | |
| Eventide Asset Management | $49.73M | 2.91 | 6.81M | +0.11% | +$54,560.20 | 0.8 | |
| Geode Capital Management | $38.03M | 2.23 | 5.21M | +4.27% | +$1.56M | <0.01 | |
| T. Rowe Price | $28.57M | 1.67 | 3.91M | +68.03% | +$11.57M | <0.01 | |
| Macquarie Group | $26.91M | 1.58 | 3.69M | New | +$26.91M | 0.03 | |
| Voloridge Investment Management, LLC | $24.1M | 1.41 | 3.3M | +190.31% | +$15.8M | 0.09 | |
| Nuveen | $23.32M | 1.37 | 3.19M | +51.54% | +$7.93M | 0.01 | |
| Two Sigma | $18.7M | 1.1 | 2.56M | +445.9% | +$15.28M | 0.03 | |
| Morgan Stanley | $17.58M | 1.03 | 2.41M | -24.85% | -$5.81M | <0.01 | |
| Redmile Group | $16.02M | 0.94 | 2.19M | New | +$16.02M | 0.16 | |
| Northern Trust | $15.69M | 0.92 | 2.15M | -1.78% | -$284,028.40 | <0.01 | |
| Oracle Investment Management Inc | $14.89M | 0.87 | 2.04M | +135.88% | +$8.58M | 2.01 | |
| Goldman Sachs | $14.54M | 0.85 | 1.99M | +80.38% | +$6.48M | <0.01 | |
| Charles Schwab | $13.53M | 0.79 | 1.85M | +2.04% | +$270,793.50 | <0.01 | |
| Helm Capital Management LLC | $13.26M | 0.78 | 1.82M | -54.73% | -$16.03M | 0.39 | |
| Susquehanna International Group | $11.95M | 0.7 | 1.64M | -36.79% | -$6.95M | 0.01 | |
| Cubist Systematic Strategies | $10.27M | 0.6 | 1.41M | +953.84% | +$9.3M | 0.09 | |
| Deutsche Bank | $9.74M | 0.57 | 1.33M | +17.81% | +$1.47M | <0.01 | |
| Millennium Management LLC | $9.63M | 0.56 | 1.32M | New | +$9.63M | 0.01 | |
| Jane Street Capital | $8.91M | 0.52 | 1.22M | +11.39% | +$911,441.47 | 0.01 | |
| Rafferty Asset Management Llc | $7.7M | 0.45 | 1.06M | -23.28% | -$2.34M | 0.02 | |
| Lion Point Capital LP | $7.64M | 0.45 | 1.05M | -9.12% | -$766,499.99 | 14.81 | |
| Bank of America | $7.61M | 0.45 | 1.04M | +126.74% | +$4.26M | <0.01 | |
| BNY Mellon | $7.05M | 0.41 | 965,763 | -8.55% | -$659,467.32 | <0.01 | |
| Citigroup | $6.89M | 0.4 | 943,493 | +69.82% | +$2.83M | 0.01 | |
| UBS | $6.46M | 0.38 | 884,503 | +47.75% | +$2.09M | <0.01 | |
| Schonfeld Group | $5.58M | 0.33 | 764,024 | New | +$5.58M | 0.03 | |
| Standard Life | $5.12M | 0.3 | 700,865 | -15.93% | -$969,067.80 | 0.01 | |
| Pekin Singer Strauss Asset Management Il | $3.96M | 0.23 | 542,660 | -29.65% | -$1.67M | 0.36 | |
| Russell Investments Group Ltd | $3.91M | 0.23 | 536,297 | +100.67% | +$1.96M | 0.01 | |
| Td Asset Management Inc | $3.73M | 0.22 | 510,336 | +75.41% | +$1.6M | <0.01 | |
| Barclays | $3.35M | 0.2 | 459,268 | -78.99% | -$12.6M | <0.01 | |
| Swiss National Bank | $3.35M | 0.2 | 458,300 | +6.73% | +$210,970.00 | <0.01 | |
| Citadel Advisors LLC | $3.29M | 0.19 | 450,705 | +171.01% | +$2.08M | <0.01 | |
| Two Sigma Advisers LP | $3.17M | 0.19 | 433,600 | New | +$3.17M | 0.01 | |
| Seven Eight Capital Lp | $2.73M | 0.16 | 374,151 | +2,230.87% | +$2.61M | 0.29 | |
| The Manufacturers Life Insurance Company | $2.64M | 0.16 | 361,774 | +51.76% | +$900,681.23 | <0.01 | |
| Trexquant Investment LP | $2.58M | 0.15 | 353,709 | New | +$2.58M | 0.05 | |
| Simplify Asset Management Inc | $2.56M | 0.15 | 350,000 | 0% | +$0 | 0.25 | |
| RhumbLine Advisers | $2.46M | 0.14 | 337,574 | +3.31% | +$78,912.71 | <0.01 | |
| Ubs Asset Management Americas Inc | $2.26M | 0.13 | 309,097 | -0.5% | -$11,307.70 | <0.01 | |
| New York State Common Retirement Fund | $2.07M | 0.12 | 283,712 | +0.02% | +$467.18 | <0.01 | |
| Natixis | $2.01M | 0.12 | 275,968 | New | +$2.01M | 0.01 | |
| Voya Investment Management LLC | $2.01M | 0.12 | 275,690 | -45.5% | -$1.68M | <0.01 | |
| Marshall Wace | $1.97M | 0.12 | 270,466 | New | +$1.97M | <0.01 | |
| Credit Suisse | $1.98M | 0.12 | 271,263 | +1.85% | +$35,967.10 | <0.01 | |
| J. Goldman & Company | $1.96M | 0.12 | 268,854 | -83.19% | -$9.71M | 0.07 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.